Northland Securities Reiterates Market Perform Rating for Oncternal Therapeutics (NASDAQ:ONCT)

Oncternal Therapeutics (NASDAQ:ONCT)‘s stock had its “market perform” rating reaffirmed by equities researchers at Northland Securities in a report released on Thursday, Benzinga reports. They currently have a $2.00 price objective on the stock. Northland Securities’ target price would indicate a potential upside of 36.99% from the company’s current price.

Other analysts have also recently issued reports about the stock. StockNews.com assumed coverage on shares of Oncternal Therapeutics in a report on Sunday, September 8th. They set a “hold” rating for the company. HC Wainwright decreased their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Finally, Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday.

Oncternal Therapeutics Stock Down 14.1 %

Shares of NASDAQ:ONCT opened at $1.46 on Thursday. The company’s fifty day moving average is $5.37 and its two-hundred day moving average is $7.48. The company has a market cap of $4.32 million, a P/E ratio of -0.12 and a beta of 1.39. Oncternal Therapeutics has a 12-month low of $1.32 and a 12-month high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The firm had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same period in the previous year, the firm earned ($3.00) earnings per share. Equities research analysts anticipate that Oncternal Therapeutics will post -11.4 earnings per share for the current year.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is owned by institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.